Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies
- 1 September 2013
- journal article
- Published by Elsevier BV in Virology
- Vol. 444 (1-2), 329-336
- https://doi.org/10.1016/j.virol.2013.06.029
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious VirusGastroenterology, 2011
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionNew England Journal of Medicine, 2009
- Avoiding therapeutic pitfalls: The rational use of specifically targeted agents against hepatitis C infectionHepatology, 2008
- Black patients with chronic hepatitis C have a lower sustained viral response rate than non‐Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*Journal of Viral Hepatitis, 2005
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspectiveVirus Research, 2005
- HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation TimeScience, 1996